Department of Stroke and Neuroscience, Charing Cross Hospital, Imperial College London NHS Healthcare Trust, London, UK.
Department of Brain Sciences, Imperial College London, London, UK.
J Neurol. 2023 Dec;270(12):5827-5834. doi: 10.1007/s00415-023-11926-5. Epub 2023 Aug 18.
Mechanical thrombectomy (MT) remains an effective treatment for patients with acute ischemic stroke receiving oral anticoagulation (OAC) and large vessel occlusion (LVO). However, to date, it remains unclear whether MT is safe in patients on treatment with OAC.
In our study, we performed a propensity-matched analysis to investigate the safety and efficacy of MT in patients with acute ischemic stroke receiving anticoagulants. A propensity score method was used to target the causal inference of the observational study design.
This observational, prospective, single-centre study included consecutive patients with acute LVO ischemic stroke of the anterior circulation. Demographic, neuro-imaging and clinical data were collected and compared according to the anticoagulation status at baseline, patients on OAC vs those not on OAC. The primary study outcomes were the occurrence of any intracerebral haemorrhage (ICH) and symptomatic ICH. The secondary study outcomes were functional independence at 90 days after stroke (defined as modified Rankin Scale (mRS) scores of 0 through 2), mortality at 3 months and successful reperfusion rate according to the modified treatment in cerebral infarction (mTICI) score.
Overall, our cohort included 573 patients with acute ischemic stroke and LVO treated with MT. After propensity score matching, 495 patients were matched (99 OAC group vs 396 no OAC group). There were no differences in terms of clinical characteristics between the two groups, except for the rate of intravenous thrombolysis less frequently given in the OAC group. There was no significant difference in terms of the rate of any ICH and symptomatic ICH between the two groups. With regards to the secondary study outcome, there was no significant difference in terms of the rate of successful recanalization post-procedure and functional independence at 3 months between the two groups. Patients in the OAC group showed a reduced mortality rate at 90 days compared to the patients with no previous use of anticoagulation (20.2% vs 21.2%, p = 0.031). Logistic regression analysis did not reveal a statistically significant influence of the anticoagulation status on the likelihood of any ICH (OR = 0.95, 95% CI = 0.46-1.97, p = 0.900) and symptomatic ICH (OR = 4.87, 95% CI = 0.64-37.1, p = 0.127). Our analysis showed also that pre-admission anticoagulant use was not associated with functional independence at 90 days after stroke (OR = 0.76, 95% CI = 0.39-1.48, p = 0.422) and rate of successful reperfusion (OR = 0.81, 95% CI = 0.38-1.72, p = 0.582).
According to our findings anticoagulation status at baseline did not raise any suggestion of safety and efficacy concerns when MT treatment is provided according to the standard guidelines. Confirmation of these results in larger controlled prospective cohorts is necessary.
机械血栓切除术(MT)仍然是接受口服抗凝剂(OAC)和大血管闭塞(LVO)的急性缺血性脑卒中患者的有效治疗方法。然而,迄今为止,尚不清楚 MT 在接受 OAC 治疗的患者中是否安全。
在我们的研究中,我们进行了倾向评分匹配分析,以研究急性缺血性脑卒中接受抗凝治疗的患者中 MT 的安全性和疗效。使用倾向评分方法针对观察性研究设计的因果推断。
这项观察性、前瞻性、单中心研究纳入了连续的前循环急性 LVO 缺血性脑卒中患者。收集人口统计学、神经影像学和临床数据,并根据基线时的抗凝状态、接受 OAC 的患者与未接受 OAC 的患者进行比较。主要研究结果是任何颅内出血(ICH)和症状性 ICH 的发生。次要研究结果是卒中后 90 天的功能独立性(定义为改良 Rankin 量表(mRS)评分 0-2)、3 个月时的死亡率和根据改良脑梗死治疗(mTICI)评分的成功再灌注率。
总体而言,我们的队列包括 573 例接受 MT 治疗的急性缺血性脑卒中合并 LVO 患者。在进行倾向评分匹配后,495 例患者匹配(99 例 OAC 组和 396 例无 OAC 组)。两组在临床特征方面无差异,除了 OAC 组更频繁地给予静脉溶栓治疗。两组间任何 ICH 和症状性 ICH 的发生率无显著差异。关于次要研究结果,两组间术后再通率和 3 个月时的功能独立性无显著差异。与未接受抗凝治疗的患者相比,OAC 组的 90 天死亡率较低(20.2%比 21.2%,p=0.031)。Logistic 回归分析未显示抗凝状态对任何 ICH(OR=0.95,95%CI=0.46-1.97,p=0.900)和症状性 ICH(OR=4.87,95%CI=0.64-37.1,p=0.127)发生的可能性有统计学显著影响。我们的分析还表明,入院前使用抗凝剂与卒中后 90 天的功能独立性(OR=0.76,95%CI=0.39-1.48,p=0.422)和成功再灌注率(OR=0.81,95%CI=0.38-1.72,p=0.582)无关。
根据我们的发现,根据标准指南进行 MT 治疗时,基线时的抗凝状态并未引起任何安全性和疗效问题的关注。有必要在更大的对照前瞻性队列中确认这些结果。